EVI1在急性髓系白血病中的研究进展

doi:10.3760/cma.j.cn371439-20231218-00078

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (7): 474-477.doi: 10.3760/cma.j.cn371439-20231218-00078

EVI1在急性髓系白血病中的研究进展

吴市委, 裴康佳, 张东星, 秦占雨, 郭树霞()

河南中医药大学第五临床医学院（郑州人民医院）血液科，郑州 450000

收稿日期:2023-12-18 修回日期:2024-03-27 出版日期:2024-07-08 发布日期:2024-08-14
通讯作者: 郭树霞，Email： guosx118@126.com
基金资助:
河南省科技攻关项目(212102310786)

Advances in the study of EVI1 in acute myeloid leukemia

Wu Shiwei, Pei Kangjia, Zhang Dongxing, Qin Zhanyu, Guo Shuxia()

Department of Hematology， Fifth Clinical Medica College of Henan University of Chinese Medicine （People's Hospital of Zhengzhou）， Zhengzhou 450000， China

Received:2023-12-18 Revised:2024-03-27 Online:2024-07-08 Published:2024-08-14
Contact: Guo Shuxia， Email： guosx118@126.com
Supported by:
Henan Provincial Program for Science and Technology Development(212102310786)

摘要/Abstract

摘要：

急性髓系白血病（AML）是血液系统常见的恶性疾病，伴EVI1高表达患者占成人AML的8%~10%。研究表明EVI1高表达在AML的治疗与预后中发挥重要作用。近些年来研究人员不断揭示EVI1的结构与作用，但其介导AML的机制尚未完全明确。系统探讨EVI1在AML中的作用可为EVI1高表达AML患者的精准化治疗提供有益参考。

关键词: 髓系亲嗜性病毒整合位点1蛋白, 白血病, 髓样, 急性, 基因表达, 治疗

Abstract:

Acute myeloid leukemia （AML） is a common malignant disease of the hematological system， with high EVI1 expression accounting for 8%-10% of adult AML. Studies have shown that high EVI1 expression plays an important role in the treatment and prognosis of AML. In recent years， researchers have continuously revealed the structure and role of EVI1， but its mechanism of mediating AML has not been fully clarified. Therefore， systematically exploring the role of EVI1 in AML may provide a useful reference for the precise treatment of AML patients with high EVI1 expression.

Key words: Myeloid ecotropic viral integration site 1 protein, Leukemia, myeloid, acute, Gene expression, Therapy

吴市委, 裴康佳, 张东星, 秦占雨, 郭树霞. EVI1在急性髓系白血病中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 474-477.

Wu Shiwei, Pei Kangjia, Zhang Dongxing, Qin Zhanyu, Guo Shuxia. Advances in the study of EVI1 in acute myeloid leukemia[J]. Journal of International Oncology, 2024, 51(7): 474-477.

参考文献 26

[1]	陈晓奉, 王蒙, 李忠玉, 等. Venetoclax联合化疗治疗复发/难治性急性髓系白血病的临床研究[J]. 中国全科医学, 2022, 25(8): 957-962. DOI: 10.12114/j.issn.1007-9572.2022.02.005.
[2]	Lux S, Milsom MD. EVI1-mediated programming of normal and malignant hematopoiesis[J]. Hemasphere, 2023, 7(10): e959. DOI: 10.1097/HS9.0000000000000959. pmid: 37810550
[3]	Nabil R, Abdellateif MS, Gamal H, et al. Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia[J]. Leuk Res, 2023, 126: 107019. DOI: 10.1016/j.leukres.2023.107019.
[4]	Liang BY, Wang J. EVI1 in leukemia and solid tumors[J]. Cancers (Basel), 2020, 12(9): 2667. DOI:10.3390/cancers12092667.
[5]	Schmoellerl J, Barbosa IAM, Minnich M, et al. EVI1 drives leukemogenesis through aberrant ERG activation[J]. Blood, 2023, 141(5): 453-466. DOI: 10.1182/blood.2022016592.
[6]	Paredes R, Schneider M, Pearson S, et al. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle[J]. Mol Biol Rep, 2020, 47(10): 8293-8300. DOI: 10.1007/s11033-020-05829-1.
[7]	Nagai K, Niihori T, Muto A, et al. Mecom mutation related to radioulnar synostosis with amegakaryocytic thrombocytopenia reduces HSPCs in mice[J]. Blood Adv, 2023, 7(18): 5409-5420. DOI: 10.1182/bloodadvances.2022008462.
[8]	Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression[J]. Cancer Cell, 2014, 25(4): 415-427. DOI: 10.1016/j.ccr.2014.02.008. pmid: 24703906
[9]	Kreider BL, Orkin SH, Ihle JN. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene[J]. Proc Natl Acad Sci U S A, 1993, 90(14): 6454-6458. DOI: 10.1073/pnas.90.14.6454.
[10]	Morishita K, Parganas E, Matsugi T, et al. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor[J]. Mol Cell Biol, 1992, 12(1): 183-189. DOI:10.1128/mcb.12.1.183-189.1992. pmid: 1370341
[11]	Yamaoka A, Suzuki M, Katayama SR, et al. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis[J]. Blood Adv, 2020, 4(8): 1722-1736. DOI: 10.1182/bloodadvances.2019000978. pmid: 32330245
[12]	Mittal N, Li LP, Sheng Y, et al. A critical role of epigenetic inactivation of miR-9 in EVI1^high pediatric AML[J]. Mol Cancer, 2019, 18(1): 30. DOI:10.1186/s12943-019-0952-z. pmid: 30813931
[13]	Lang WJ, Han XF, Cai JY, et al. Ectopic viral integration site-1 oncogene promotes NRAS pathway through epigenetic silencing of microRNA-124 in acute myeloid leukemia[J]. Cell Signal, 2022, 99: 110402. DOI: 10.1016/j.cellsig.2022.110402.
[14]	Jiang M, Zou XQ, Huang WH. Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3-mediated TGFβ/EMT signaling pathway[J]. Oncol Lett, 2018, 16(2): 2701-2708. DOI: 10.3892/ol.2018.8890. pmid: 30013666
[15]	Kotaki R, Higuchi H, Ogiya D, et al. Imbalanced expression of polycistronic miRNA in acute myeloid leukemia[J]. Int J Hematol, 2017, 106(6): 811-819. DOI: 10.1007/s12185-017-2314-1. pmid: 28831750
[16]	Masamoto Y, Chiba A, Mizuno H, et al. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment[J]. Blood Adv, 2023, 7(8): 1577-1593. DOI: 10.1182/bloodadvances.2022008018.
[17]	Ayoub E, Wilson MP, McGrath KE, et al. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription[J]. Nat Commun, 2018, 9(1): 4239. DOI:10.1038/s41467-018-06208-y. pmid: 30315161
[18]	Qin YZ, Zhao T, Zhu HH, et al. High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy[J]. Med Sci Monit, 2018, 24: 758-767. DOI: 10.12659/msm.905903.
[19]	Zheng Y, Huang Y, Le S, et al. High EVI1 expression predicts adverse outcomes in children with de novo acute myeloid leukemia[J]. Front Oncol, 2021: 712747. DOI: 10.3389/fonc.2021.712747.
[20]	Kiehlmeier S, Rafiee MR, Bakr A, et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia[J]. Leukemia, 2021, 35(11): 3127-3138. DOI: 10.1038/s41375-021-01235-z. pmid: 33911178
[21]	Yamamoto H, Lu J, Oba GYY, et al. MiR-133 regulates Evi1 expression in AML cells as a potential therapeutic target[J]. Sci Rep, 2016, 6(1): 19204. DOI:10.1038/srep19204.
[22]	Paubelle E, Plesa A, Hayette S, et al. Efficacy of all-trans-retinoic acid in high-risk acute myeloid leukemia with overexpression of EVI1[J]. Oncol Ther, 2019, 7(2): 121-130. DOI: 10.1007/s40487-019-0095-9.
[23]	Nguyen CH, Bauer K, Hackl H, et al. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia[J]. Cell Death Dis, 2019, 10(12): 944. DOI:10.1038/s41419-019-2172-2. pmid: 31822659
[24]	Nguyen CH, Grandits AM, Vassiliou GS, et al. Evi1 counteracts anti-leukemic and stem cell inhibitory effects of all-trans retinoic acid on Flt3-ITD/Npm1c-driven acute myeloid leukemia cells[J]. Biomedicines, 2020, 8(10): 385. DOI:10.3390/biomedicines8100385.
[25]	Saito Y, Kaneda K, Suekane A, et al. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56[J]. Leukemia, 2013, 27(8): 1637-1649. DOI: 10.1038/leu.2013.75. pmid: 23478665
[26]	Saha HR, Kaneda-Nakashima K, Shimosaki S, et al. Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression[J]. Sci Rep, 2018, 8(1): 13741. DOI:10.1038/s41598-018-32205-8. pmid: 30214063

EVI1在急性髓系白血病中的研究进展

Advances in the study of EVI1 in acute myeloid leukemia

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于新生, 任磊, 卢晓光. 现代质子放疗和光子放疗的争论与思考[J]. 国际肿瘤学杂志, 2024, 51(7): 411-416.
[2]	刘晶, 张俊. 放射性碘难治性分化型甲状腺癌再分化治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 464-467.
[3]	韩艺, 张同梅, 齐菲, 张泳. 肺大细胞神经内分泌癌临床分子诊断和治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 468-473.
[4]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[5]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[10]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[11]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[12]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[13]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[14]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[15]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.